Imagine living with hemophilia, where even minor injuries can lead to serious bleeding. This condition affects the blood's ability to clot, making everyday activities a challenge. For those with inhibitors, the situation is even more complex, as their bodies resist standard treatments. In a recent study, a new drug called concizumab was tested to see if it could help. Patients using concizumab experienced only about one bleeding episode over a year, compared to those not on the treatment, who faced many more. This means fewer interruptions in their daily lives and less anxiety about bleeding. While the results are promising, it's important to note that this treatment is still being evaluated, and more research is needed to confirm its long-term safety and effectiveness. However, for many living with hemophilia, concizumab offers hope for a more manageable life.
Concizumab Reduces Bleeding in Hemophilia with Inhibitors: Median ABR 0.8 at 56 WeeksCould a New Treatment Change the Lives of People with Hemophilia?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider concizumab for reducing bleeding in hemophilia A/B with inhibitors due to its proven efficacy.
The phase 3 explorer7 study evaluated the efficacy and safety of concizumab, an anti-TFPI monoclonal antibody, for prophylaxis in patients with hemophilia A or B with inhibitors (HAwI/HBwI). The study included 133 male patients aged ≥12 years, with 80 having hemophilia A and 53 having hemophilia B. Patients were randomized in a 1:2 ratio to either no prophylaxis (group 1) or concizumab prophylaxis (group 2), with additional nonrandomized groups (3 and 4) receiving concizumab. After a minimum of 24 weeks, patients in the no prophylaxis group were allowed to switch to concizumab. At the 56-week cutoff, the primary endpoint showed a significant reduction in the median annualized bleeding rate (ABR) for spontaneous and traumatic bleeding episodes in patients receiving concizumab, with a median ABR of 0.8 (IQR, 0.0-3.2), consistent with earlier results at the 32-week cutoff. Secondary endpoints included pharmacokinetics and pharmacodynamics, which demonstrated stable concizumab and free-TFPI concentrations over time. Safety analysis revealed no new adverse events, confirming the drug's safety profile. The study results support the longer-term efficacy and safety of concizumab prophylaxis in reducing bleeding episodes in HAwI/HBwI patients, providing a viable prophylactic option for this population.
What this means for you:
Concizumab could be a game-changer for people with hemophilia, offering hope for fewer bleeding episodes. More on Hemophilia A
Meta-analysis finds non-clotting factor therapies reduce bleeding in congenital hemophilia
Can new therapies help people with hemophilia bleed less and live better?
This meta-analysis of 6 RCTs (397 participants) synthesizes evidence on non-clotting factor therapies for bleed prevention in congenital hem…
For people with hemophilia, frequent bleeding can disrupt daily life and cause pain.
Gene therapy reduces bleeding rates and factor use in adults with severe hemophilia A
Can gene therapy reduce bleeding and treatment burden for adults with severe hemophilia A?
A systematic review and meta-analysis of adults with severe/moderately severe hemophilia A found gene therapy reduced annualized bleeding ra…
For adults with severe hemophilia A, gene therapy may offer a way to bleed less and rely far less on regular infusions.
Damoctocog alfa pegol shows safety and maintained bleed protection in children with severe haemophilia A
Study finds haemophilia drug safe and effective in children over six months
A phase 3, open-label, single-arm study of 35 previously treated children aged 7 to <12 years with severe haemophilia A found no adverse eve…
A haemophilia drug prevented bleeds in children aged 7 to under 12, with no severe side effects and no one stopping treatment due to bad rea…
Phase 3 trial of damoctocog alfa pegol in previously treated children with severe haemophilia A
Phase 3 trial studies new treatment for severe haemophilia A in children
A phase 3 clinical trial evaluated damoctocog alfa pegol in previously treated children aged 7 to 12 years with severe haemophilia A.
A new treatment for severe haemophilia A in children aged 7 to 12 is being tested in a Phase 3 trial to check its safety and effectiveness.
View Original Abstract ↓
Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI/HBwI). Male patients aged ≥12 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After ≥24 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After ≥24 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (≥1 year) efficacy and safety results of concizumab prophylaxis for HAwI/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
From Other Specialties
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…
Social and emotional skills training shows non-significant reductions in loneliness among children and adolescents
Social and Emotional Training Shows Promise for Youth Loneliness
This meta-analysis of 18 studies evaluated interventions targeting loneliness, including social and emotional skills training, in youth aged…
New research looks at how social and emotional skills training can help reduce feelings of loneliness in children and teenagers.